Research directory
Peptide compounds, organized by evidence and regulatory status
A curated reference of peptide research compounds drawn from public biomedical databases. Each entry lists mechanism summaries, regulatory status, evidence quality, safety flags, and links to peer-reviewed literature — never dosing, protocols, or sourcing.
AOD-9604
hGH fragment 176-191
Synthetic analog of the C-terminal fragment of human growth hormone studied for lipolytic activity in animal models. Failed to demonstrate efficacy...
Cagrilintide
Metabolic & GLP-1/GIP Agonists reference entry
Long-acting amylin analog studied in Phase 3 development, typically in combination with semaglutide (CagriSema).
Liraglutide
Metabolic & GLP-1/GIP Agonists reference entry
GLP-1 receptor agonist with an albumin-binding fatty acid linker. FDA-approved for type 2 diabetes and obesity.
Retatrutide
Metabolic & GLP-1/GIP Agonists reference entry
Investigational triple agonist (GLP-1 / GIP / glucagon receptors) currently in Phase 3 development.
Semaglutide
Metabolic & GLP-1/GIP Agonists reference entry
Long-acting GLP-1 receptor agonist studied extensively in type 2 diabetes and chronic weight management.
Tirzepatide
Metabolic & GLP-1/GIP Agonists reference entry
Dual GLP-1/GIP receptor agonist FDA-approved for type 2 diabetes and chronic weight management.